1% in. ≤20 age stage, 61.5% in 20–39 age stage, 40.4% in ≥40 age stage. There were increase about the percentage

of patients with cHBcAg c-nHBcAg expression following the age increase. (4.6%/4.6%; 19.3%/7.7%; 26.9%/20.4%), but there was no significant difference (X2 = 8.94, P > 0.05). Conclusion: The expression of HBcAg for the patients with chronic hepatitis B virus infection was related to the serum HBeAg expression. The histologic grade of hepatitis were Erlotinib in vivo significantly correlated with the subcellular localization of intrahepatic HBcAg. There were different characteristic for the expression of HBcAg in the different age stage, perhaps due to the different natural history stage. Key Word(s): 1. chronic hepatitis B; 2. HBeAg; 3. HBcAg; Presenting Author: NINGNING ZHANG Additional Authors: WEI LU Corresponding Author: NINGNING ZHANG Affiliations:

Tianjin Second People’s Hospital Objective: Introduction: Hepatocellular carcinoma (HCC) is the third most common cause of death worldwide. The risk of developing HCC in patients suffering from cirrhosis is increased in the setting of chronic HCV. Objective: To determine the tumor recurrence, safety, and survival outcomes of HCC patients with chronic hepatitis C (genotype 1) infection after receiving radiofrequency ablation (RFA) and antiviral therapy using peg-alfa interferon and weight based ribavirin. Methods: Using our institution’s database, we identified all patients with chronic Hepatitis C (HCV) genotype 1 and small HCC (less EX 527 price than 3.0 cm) between December 2007 – December 2010. The following data was from extracted; sustained virological rate (SVR), tumor necrosis rate and tumor recurrent rate, and 1-year survival rate. HCC recurrence and monitoring was done using serum a-fetoprotein (AFP) test and radiological findings. Results: During the study period, there were 75 patients (42 males, 33 females, age 43 years (32–54) with HCC (≤3 cm) and HCV (genotype 1). We divided the patients into two

groups: control group (n = 33) received RFA only and treatment group (n = 42) received RFA and peg-alfa interferon with weight based ribavirin. The tumor complete necrosis rate at three months in the control group was 24.24% versus Rx group was 50% (P < 0.05). The one-year viral suppression in the control group was 30.3% versus Rx group 64.28% (P < 0.05). The HCC recurrence rate in the control group was 38.39% versus Rx group 7.1% (P < 0.05). The one-year survival rate was 30.3% in control group versus Rx group 61.9% (P < 0.05). Conclusion: The above results demonstrate potential benefits of adding antiviral therapy and suppressing HCV virus in patients with compensated cirrhosis and small HCC undergoing RFA. Further trials involving larger number of patients are needed to delineate the overall impact of HCV eradication in the patient with compensated cirrhosis and HCC.